Chinese expert consensus on the risk assessment and management of panvascular disease inpatients with type 2 diabetes mellitus (2022 edition)-Reference-Cited by-同舟云学术

Chinese expert consensus on the risk assessment and management of panvascular disease inpatients with type 2 diabetes mellitus (2022 edition)

Published:2022-10 Issue:4 Volume:7 Page:162-177
ISSN:2470-7511
Container-title:Cardiology Plus
language:en
Short-container-title:

Author:

Chu Xi¹,Feng Bo²,Ge Junbo³⁴,Guo Lixin⁵,Huo Yong⁶,Ji Linong⁷,Jia Qian⁸,Jiang Song⁹,Li Yong¹⁰,Liu Fang¹¹,Liu Xinfeng¹²,Liu Yuping¹³,Lu Bin¹⁰,Lv Ankang¹⁴,Wang Yongjun⁸,Weng Jianping¹⁵,Zeng Qiang¹⁶,Zhang Yingmei³,Zhou Jingmin³,

Affiliation:

1. Department of Urology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

2. Department of Endocrinology, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.

3. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

4. Institute of Cardiovascular Diseases, China National Clinical Research Center for Interventional Medicine, Shanghai 200032, China.

5. Beijing Hospital, Tsinghua University School of Medicine, Beijing 100005, China.

6. Department of Cardiology, Peking University First Hospital, Peking University School of Medicine, Beijing 100034, China.

7. Department of Endocrinology and Metabolism, Peking University People’s Hospital, Peking University School of Medicine, Beijing 100034, China.

8. Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.

9. Department of Cardiology, National Clinical Research Center for Kidney Diseases, Nanjing General Hospital of Nanjing Military Command, Nanjing 210016, China.

10. Department of Cardiology, Huashan Hospital, Fudan University, Shanghai 311599, China.

11. Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai First People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200940, China.

12. Stroke Center and Department of Neurology, The First Affiliated Hospital of the University of Science and Technology of China, Shanghai 200123, China.

13. Health Management Center, Sichuan Provincial People’s Hospital, Sichuan Academy of Medical Sciences, Chengdu 610072, China.

14. Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

15. Institute of Endocrine Metabolic Diseases, The First Affiliated Hospital of the University of Science and Technology of China, Clinical Research Hospital of Chinese Academy of Sciences, University of Science and Technology of China, Hefei 230022, China.

16. Health Management Institute, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Bejing 100089, China.

Abstract

Panvascular disease is not only a common comorbidity of type 2 diabetes mellitus (T2DM) but also the leading cause of disability and death in T2DM patients. To promote multidisciplinary cooperation and integration for early detection of panvascular disease in patients with T2DM, a group of Chinese researchers in the fields of cardiovascular disease, endocrinology, nephrology, neurology, and health management led by the Chinese Society of Cardiology and Chinese Medical Association, formed a “Chinese Expert Consensus on Risk Assessment and Management of Panvascular Disease in Patients with Type 2 Diabetes” study group to review the latest evidence and major developments in relevant domestic and international disciplines to develop this consensus. The consensus covers the epidemiological characteristics, pathophysiological mechanisms, multidisciplinary collaborative treatments, and risk assessment and management of panvascular disease in patients with T2DM, with an emphasis on early-risk assessment of panvascular disease in patients with T2DM, including the assessment of risk factors, vascular structure and function, and target organ damage at least once a year. In addition, this consensus emphasized that managing panvascular disease in patients with T2DM requires the involvement of both patients and multidisciplinary physicians, and reinforces the importance of controlling blood glucose, blood pressure, and lipids and anti-platelet therapy in addition to lifestyle interventions. This consensus will help guide and assist clinicians regarding the standardized and comprehensive management of panvascular disease in patients with T2DM and improve patient prognosis.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference145 articles.

1. Deepening the concept of systems biology to promote the development of the discipline of panvascular medicine.;Ge;Chin J Cardiol,2016

2. Panvascular disease prevention and control-from disease treatment to comprehensive management.;Yang;Chin J Cardiol (online edition),2021

3. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.;Zhou;Lancet,2019

4. Summary of the 2021 China Cardiovascular Health and Disease Report.

5. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.;Lancet,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitochondrial dysfunction in type 2 diabetes: A neglected path to skeletal muscle atrophy;World Journal of Orthopedics;2024-02-18

2. Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets;Signal Transduction and Targeted Therapy;2023-11-20

3. Early detection of type 2 diabetes risk: limitations of current diagnostic criteria;Frontiers in Endocrinology;2023-11-09

4. Unwavering excellence: How to be a competent cardiovascular doctor in “panvascular medicine +”;The Innovation;2023-09